Tumour necrosis factor a as a therapeutic target for immune-mediated inflammatory diseases

被引：42

作者：

Taylor, PC ^{[1
]}

Williams, RO ^{[1
]}

Feldmann, M ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, Fac Med, London W68LH, England

来源：

CURRENT OPINION IN BIOTECHNOLOGY | 2004年 / 15卷 / 06期

关键词：

D O I：

10.1016/j.copbio.2004.09.005

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Preclinical studies have identified and validated tumour necrosis factor alpha (TNFalpha) as a key disease molecule and therapeutic target for immunotherapeutic intervention in many immune-mediated inflammatory diseases. Clinical indications include rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis. Recent clinical findings indicate that many chronic inflammatory disorders share certain pathogenic pathways, whereas others are limited to particular disease phenotypes. Better understanding of these pathogenic pathways will inform the development of new therapeutic approaches leading to more complete and sustained disease remissions.

引用

收藏

页码：557 / 563

页数：7

相关论文

共 79 条

[11] Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis [J].

Catrina, AI ;

Lampa, J ;

Ernestam, S ;

af Klint, E ;

Bratt, J ;

Klareskog, L ;

Ulfgren, AK .

RHEUMATOLOGY, 2002, 41 (05) :484-489

[12]

Charles P, 1999, J IMMUNOL, V163, P1521

[13] Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial [J].

Chaudhari, U ;

Romano, P ;

Mulcahy, LD ;

Dooley, LT ;

Baker, DG ;

Gottlieb, AB .

LANCET, 2001, 357 (9271) :1842-1847

[14] Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].

Chung, ES ;

Packer, M ;

Lo, KH ;

Fasanmade, AA ;

Willerson, JT .

CIRCULATION, 2003, 107 (25) :3133-3140

[15] Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - A randomized, controlled trial [J].

Davis, JC ;

van der Heijde, D ;

Braun, J ;

Dougados, M ;

Cush, J ;

Clegg, DO ;

Kivitz, A ;

Fleischmann, R ;

Inman, R ;

Tsuji, W .

ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3230-3236

[16] Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease [J].

Di Sabatino, A ;

Ciccocioppo, R ;

Cinque, B ;

Millimaggi, D ;

Morera, R ;

Ricevuti, L ;

Cifone, MG ;

Corazza, GR .

GUT, 2004, 53 (01) :70-77

[17]

Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6

[18] ELEVATED TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) BIOLOGICAL-ACTIVITY IN PSORIATIC SKIN-LESIONS [J].

ETTEHADI, P ;

GREAVES, MW ;

WALLACH, D ;

ADERKA, D ;

CAMP, RDR .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1994, 96 (01) :146-151

[19] Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial [J].

Farrell, RJ ;

Alsahli, M ;

Jeen, YT ;

Falchuk, KR ;

Peppercorn, MA ;

Michetti, P .

GASTROENTEROLOGY, 2003, 124 (04) :917-924

[20] Anti-TNFα therapy of rheumatoid arthritis:: what have we learned? [J].

Feldmann, M ;

Maini, RN .

ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :163-196

← 1 2 3 4 5 6 7 8 →